The position of renal denervation in treatment of hypertension: an expert consensus statement

被引：6

作者：

Zeijen, V. J. M. ^{[1
]}

Kroon, A. A. ^{[2
,3
]}

van den Born, B. H. ^{[4
]}

Blankestijn, P. J. ^{[5
]}

Meijvis, S. C. A. ^{[5
]}

Nap, A. ^{[6
]}

Lipsic, E. ^{[7
]}

Elvan, A. ^{[8
]}

Versmissen, J. ^{[9
]}

van Geuns, R. J. ^{[10
]}

Voskuil, M. ^{[11
]}

Tonino, P. A. L. ^{[12
]}

Spiering, W. ^{[13
]}

Deinum, J. ^{[14
]}

Daemen, J. ^{[1
]}

机构：

[1] Erasmus MC, Dept Cardiol, Rotterdam, Netherlands

[2] Maastricht Univ, Dept Internal Med, Med Ctr, Maastricht, Netherlands

[3] Cardiovasc Res Inst Maastricht, Maastricht, Netherlands

[4] Univ Amsterdam, Dept Vasc Med, Med Ctr, Amsterdam, Netherlands

[5] Univ Med Ctr Utrecht, Dept Nephrol & Hypertens, Utrecht, Netherlands

[6] Univ Amsterdam, Dept Cardiol, Med Ctr, Amsterdam, Netherlands

[7] Univ Med Ctr Groningen, Dept Cardiol, Groningen, Netherlands

[8] Isala Heart Ctr, Dept Cardiol, Zwolle, Netherlands

[9] Erasmus MC, Dept Internal Med, Rotterdam, Netherlands

[10] Radboud Univ Nijmegen, Dept Cardiol, Med Ctr, Nijmegen, Netherlands

[11] Univ Med Ctr Utrecht, Dept Cardiol, Utrecht, Netherlands

[12] Catharina Hosp, Dept Cardiol, Eindhoven, Netherlands

[13] Univ Med Ctr Utrecht, Dept Vasc Med, Utrecht, Netherlands

[14] Radboud Univ Nijmegen, Dept Internal Med, Med Ctr, Nijmegen, Netherlands

来源：

NETHERLANDS HEART JOURNAL | 2023年 / 31卷 / 01期

关键词：

Netherlands; Consensus; Sympathectomy; Hypertension; Patient care; BLOOD-PRESSURE RESPONSE; RESISTANT HYPERTENSION; COST-EFFECTIVENESS; CATHETER; ADHERENCE; TRIAL; MEDICATION; THERAPY; SAFETY; METAANALYSIS;

D O I：

10.1007/s12471-022-01717-4

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Hypertension is an important risk factor for cardiovascular disease. In the Netherlands, there are approximately 2.8 million people with hypertension. Despite treatment recommendations including lifestyle changes and antihypertensive drugs, most patients do not meet guideline-recommended blood pressure (BP) targets. In order to improve BP control and lower the risk of subsequent cardiovascular events, renal sympathetic denervation (RDN) has been introduced and studied as a non-pharmacological approach. While early data on the efficacy of RDN showed conflicting results, improvements in treatment protocols and study design resulted in robust new evidence supporting the potential of the technology to improve patient care in hypertensive subjects. Recently, 5 randomised sham-controlled trials demonstrated the safety and efficacy of the technology. Modelling studies have further shown that RDN is cost-effective in the Dutch healthcare setting. Given the undisputable disease burden along with the shortcomings of current therapeutic options, we postulate a new, clearly framed indication for RDN as an adjunct in the treatment of hypertension. The present consensus statement summarises current guideline-recommended BP targets, proposed workup and treatment for hypertension, and position of RDN for those patients with primary hypertension who do not meet guideline-recommended BP targets (see central illustration).

引用

页码：3 / 11

页数：9

共 76 条

[31] Cost-Effectiveness and Clinical Effectiveness of Catheter-Based Renal Denervation for Resistant Hypertension [J].